First National Trust’s Madrigal Pharmaceuticals MDGL Stock Holding History

First National Trust’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,476	Closed	-$1.14M	–	412
2025 Q3	$1.14M	Sell	2,476 -5,538	-69%	-$2.07M	0.04%	231
2025 Q2	$2.43M	Hold	8,014	–	–	0.09%	168
2025 Q1	$2.65M	Buy	8,014 +4,470	+126%	+$1.47M	0.11%	157
2024 Q4	$1.09M	Hold	3,544	–	–	0.04%	229
2024 Q3	$752K	Hold	3,544	–	–	0.03%	254
2024 Q2	$993K	Hold	3,544	–	–	0.04%	220
2024 Q1	$946K	Sell	3,544 -870	-20%	-$205K	0.04%	222
2023 Q4	$1.02M	Sell	4,414 -455	-9%	-$79.6K	0.04%	206
2023 Q3	$711K	Hold	4,869	–	–	0.03%	235
2023 Q2	$1.12M	Hold	4,869	–	–	0.05%	190
2023 Q1	$1.18M	Buy	+4,869	New	+$1.33M	0.06%	178

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First National Trust's MDGL Position: Q4 2025 in Review

First National Trust sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 2,476 shares — an estimated $1.14M sold.

First National Trust first reported a position in MDGL in Q1 2023 and held it in 11 quarters. The position peaked at $2.65M in Q1 2025. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

First National Trust reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
First National Trust sold 2,476 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $1.14M.
First National Trust first reported a position in Madrigal Pharmaceuticals in Q1 2023 and held it in 11 quarters.
First National Trust's Madrigal Pharmaceuticals position peaked at $2.65M in Q1 2025.
387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on First National Trust's 13F filing for Q4 2025, filed 9 Feb 2026.